Leveraging the Genetics of Psychiatric Disorders to Prioritize Potential Drug Targets and Compounds

Nadine Parker (PhD)[1*], Elise Koch (PhD)[1,2], Alexey A. Shadrin (PhD)[1], Julian Fuhrer (PhD)[1], Guy F. L. Hindley (MD, PhD)[1,3], Sara E. Stinson (PhD)[1], Piotr Jaholkowski (MD, PhD)[1], Markos Tesfaye (MD, PhD)[1,4], Anders M. Dale (PhD)[5-8], Thomas S. Wingo (MD, PhD)[9], Aliza P. Wingo (MD, PhD)[10,11], Oleksandr Frei (PhD)[1,12], Kevin S. O'Connell (PhD)[1], Olav B. Smeland (MD, PhD)[1+], Ole A. Andreassen (MD, PhD)[1*+]

[1] Centre for Precision Psychiatry, University of Oslo and Oslo University Hospital, Oslo, Norway
[2] Center for Psychopharmacology, Diakonhjemmet Hospital, Oslo, Norway
[3] Department of Psychiatry, Lovisenberg Diaconal Hospital, Oslo, Norway
[4] Department of Clinical Science, University of Bergen, Bergen, Norway
[5] Multimodal Imaging Laboratory, University of California San Diego, La Jolla, CA, USA
[6] Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA,
[7] Department of Neurosciences, University of California San Diego, La Jolla, CA, USA
[8] Department of Radiology, University of California, San Diego, La Jolla, CA, USA
[9] Department of Neurology, University of California, Davis, Sacramento, CA USA
[10] Department of Psychiatry, University of California, Davis, Sacramento, CA, USA
[11] Division of Mental Health, VA Medical Center, Mather, CA, USA
[12] Department of Pharmacy, Section for Pharmacology and Pharmaceutical Biosciences, University of Oslo, Oslo, Norway

* Corresponding authors
+ These authors contributed equally.

Abstract

Genetics can inform biologically relevant drug development and repurposing which may improve patient care. Here, we leverage the genetics of psychiatric disorders to prioritize potential drug targets and compounds. We used the genome-wide association studies of four psychiatric disorders [attention deficit hyperactivity disorder (ADHD), bipolar disorder, depression, and schizophrenia] and genes encoding drug targets. We conducted drug enrichment analyses incorporating the novel and biologically specific GSA-MiXeR tool. We conducted multiple molecular trait analyses using large-scale transcriptomic and proteomic datasets sampled from brain and blood tissue. This included the novel use of the UK Biobank proteomic data for a proteome-wide association study of psychiatric disorders. With the accumulated evidence, we prioritize potential drug targets and compounds for each disorder. We reveal candidate drug targets associated with a single or multiple disorders and that implicate glutamate signalling. Drug prioritization indicated genetic support for psychotropic medications including several top ranked antipsychotics for schizophrenia. We also observed genetic support for commonly used psychotropics for psychiatric treatment (e.g., clozapine, duloxetine, and lithium). Revealed opportunities for drug repurposing included cholinergic drugs for ADHD, estrogen modulators for depression, and matrix metalloproteinases for ADHD and depression. Our findings indicate the genetic liability to schizophrenia is associated with reduced brain and blood expression of *CYP2D6,* a gene encoding a metabolizer of drugs and neurotransmitters, suggesting a genetic risk for poor drug response and altered neurotransmission. Our extensive analyses highlight the utility of genetics for informing drug development and repurposing for psychiatric disorders providing novel opportunities for improving patient outcomes.



Graphical Abstract. Depicted is the series of analyses conducted to generate a list of prioritized drug targets and compounds. First pairings of genome-wide association study (GWAS) traits with drugs are generated using enrichment analyses. Next a series of molecular trait analyses are conducted to generate and rank list of potential drug targets for each GWAS trait. Finally, enrichment and molecular trait results are combined to generate a ranked list of prioritized drugs for each GWAS trait based on supporting genetic evidence. ADHD = Attention deficit hyperactivity disorder, BIP = Bipolar disorder, DEP = Depression, SCZ = Schizophrenia, DBP = Diastolic blood pressure, T2D = Type 2 diabetes, RNA = ribonucleic acid, XWAS = both transcriptome and proteome wide association studies, MR = Mendelian randomization, coloc = colocalization.

Introduction

Genetics can provide insights into the underlying mechanisms of a trait that can be leveraged to inform drug development. Drugs with supporting genetic evidence have a 2.6 times greater probability of success in development compared to drugs lacking genetic support [1]. Notably, drugs for psychiatric treatment tend to have targets with less supporting genetic evidence than drugs for respiratory, metabolic, and cardiovascular diseases [1,2]. This lack of genetically informed drug development may partly explain the poor therapeutic response, adverse drug effects, and poor treatment compliance observed in psychiatry [1,3,4]. Furthermore, complex traits, such as psychiatric disorders and other medical conditions, share associated genes to a varying degree, a concept known as pleiotropy [5]. This pleiotropy may facilitate the repurposing of drugs approved or previously investigated for different indications. Therefore, leveraging genetics to inform drug discover, target prioritization, and repurposing may help improve psychiatric treatment.

The genome-wide association study (GWAS) of various psychiatric disorders have previously been leveraged to prioritize drug targets and compounds. Some studies use GWAS to perform gene-set analyses testing for enrichment of genes encoding drug targets [6–8]. While this approach has provided genetic support for various drugs with psychiatric indications, standard tools may be biased towards drugs with many targets potentially providing less disorder specificity [9]. Moreover, disorder-associated genetic variants can modulate gene expression and protein abundance providing a link to molecular traits (i.e., genes and proteins) serving as potential drug targets [10]. Therefore, transcriptome or proteome wide association studies (i.e.,

87 TWAS or PWAS) have been used to prioritize molecular traits as potential drug
88 targets for several psychiatric disorders [11,12]. Moreover, Mendelian randomization
89 (MR) is commonly used to identify causal relationships between molecular traits and
90 psychiatric disorders [13–16]. Applying these analyses has revealed for example that
91 calcium signalling is associated with multiple psychiatric disorders [7,11,14].
92 However, many studies tend to focus on one type of molecular trait or neglect
93 bidirectional MR analyses. Also, while transcriptomic data provides greater coverage
94 of the genome, drug targets are often proteins. Therefore, leveraging both types of
95 molecular data is complementary and more comprehensive. Although studies
96 leveraging multiple methodologies and types of molecular data to inform novel drug
97 targets and indications exist [17–21], few integrate enrichment and comprehensive
98 molecular trait analyses with a focus on psychiatric disorders.
99
100 Here, we present an extensive genetic interrogation of potential drug targets and
101 compounds for attention deficit hyperactivity disorder (ADHD), bipolar disorder (BIP),
102 depression (DEP), schizophrenia (SCZ) and as comparators two traits among clinical
103 domains with strong biological support for medication development: diastolic blood
104 pressure (DBP) and type 2 diabetes (T2D). We conduct gene-set analysis
105 incorporating the novel GSA-MiXeR tool which identifies enrichment for biologically
106 specific and smaller gene-sets than common approaches [9]. We use large scale
107 molecular trait data from brain and blood tissue to identify potential drug targets.
108 Blood is more readily available than brain tissue, resulting in larger datasets, and
109 provides complementary identification of potential drug targets. We apply a series of
110 molecular trait analyses including the novel use of UK Biobank (UKB) data for PWAS

111 of psychiatric disorders. Finally, we combine results to prioritize potential drug
112 targets and compounds.
113
114

115 Materials and Methods

116 Genome Wide Association Study Summary Statistics

117 We used summary statistics from the GWAS of four major psychiatric disorders in
118 European samples. For ADHD we used a GWAS containing a total of 38,691 cases
119 and 186,843 controls [22]. For BIP we used a GWAS including 41,917 cases and
120 371,549 controls [7]. For DEP we used a GWAS by Als et al. (2022) that excluded
121 the 23andMe sample (n_{cases}=294,322 $n_{controls}$=741,438) [23]. For SCZ we used a
122 GWAS including 76,755 cases and 243,649 controls [24]. As comparators, we used
123 GWAS summary statistics for DBP containing a total of 1,076,093 individuals [25]
124 and T2D containing 80,154 cases and 853,816 controls [26]. To avoid sample
125 overlap in analyses with the UKB proteomic samples, we used summary statistics
126 which excluded the UKB sample for BIP (n_{cases}=40,463, $n_{controls}$=313,436) and DEP
127 (n_{cases}=166,773, $n_{controls}$=507,679). GWASs conducted by the Million Veterans
128 Program were used for DBP (n=220,387)[27] and T2D (n=1,042,540)[28] to avoid
129 sample overlap with blood molecular trait datasets. We chose DBP and T2D as
130 comparators for several reasons: (i) DBP and T2D are not brain-related disorders
131 and provide a non-psychiatric comparison for our approach to drug target and
132 compound prioritization, (ii) in contrast to psychiatric medications, those developed
133 for cardiovascular and metabolic conditions have more genetic support [1,2], and (iii)
134 DBP is a continuous trait with summary statistics (e.g., betas) differing from the

135 dichotomous disorder GWAS (e.g., odds-ratio/log odds-ratio) and (iv) both DBP and
136 T2D have well powered publicly available GWAS summary statistics. These
137 differences serve to enrich the assessment of our approach.
138

139 **Candidate Drug Identification**

140 To obtain drug-target genes, we used data from the Drug Gene Interaction database
141 (DGIdb; https://www.dgidb.org/)[29] which collates data from 28 different sources
142 and is a common resource for drug enrichment analyses [6,7,30,31]. The
143 Supplementary Material contains data processing details.
144

145 As our primary method to test each GWAS trait (i.e., ADHD, BIP, DEP, SCZ, DBP,
146 T2D) for drug gene-set enrichment, we used GSA-MiXeR
147 (https://github.com/precimed/gsa-mixer) [9]. GSA-MiXeR models gene-level
148 heritability enabling the estimation of heritability partitioned across gene sets and fold
149 enrichment which estimates the extent to which heritability is concentrated in a given
150 gene set (Supplementary Material). An accompanying delta AIC value is used to
151 indicate model fit where a positive value suggests good model fit. Trait-drug pairs
152 with a positive delta AIC value were considered enriched. We additionally applied a
153 gene-set analysis with MAGMA [32]. While MAGMA tends to identify enrichment
154 among larger gene-sets than GSA-MiXeR [9], our approach requires observed
155 enrichment with GSA-MiXeR and nominal significance ($p<0.05$) with MAGMA. This
156 approach provides robust and potentially clinically actionable associations. All drug
157 gene-sets with two or more genes were included in analyses.
158

159 A list of candidate drugs for each GWAS trait was determined based on enrichment
160 using both GSA-MiXeR (AIC_{delta} >0) and MAGMA ($p<0.05$) and ranked using fold
161 enrichment values from GSA-MiXeR. To assess the degree of overlapping enriched
162 drugs between GWAS traits, we used a hypergeometric test. Enriched drugs were
163 assigned an anatomic therapeutic chemical (ATC) code using classifications
164 released in June 2023 from BioPortal. To determine if Level 1 ATC codes were over-
165 represented among the candidate drugs for each GWAS trait, we used
166 hypergeometric tests.
167

168 Candidate Target Identification

169 Transcriptome- and Proteome-Wide Association Studies

170 To identify potential drug targets for each GWAS trait, we used the FUSION tool to
171 conduct a TWAS and PWAS, which we jointly refer to as XWAS [33]. For TWAS
172 using brain tissue, we used pre-computed single nucleotide polymorphism (SNP)
173 weights for 14,751 genes from the PsychENCODE sample of 1321 individuals [34].
174 For TWAS using blood tissue, we used pre-computed weights for 8,125 genes from
175 the genotype tissue expression (GTEx; n=558) resource [33,35]. For PWAS using
176 brain tissue, we used pre-computed weights for 2,745 proteins in 720 participants
177 from the Wingo et al. (2023) study [36]. For PWAS using blood tissue, we derived
178 our own weights for 2841 proteins in 33,239 participants from the UKB
179 (Supplementary Material). Since the T2D GWAS includes UKB participants, we used
180 precomputed weights for the atherosclerosis risk in communities (ARIC: n=7,213,
181 $n_{proteins}$=1,348) sample and a separate GWAS which excluded the ARIC sample [37].

182 We performed correction for multiple comparisons across all XWAS analyses using
183 the Benjamini-Hochberg method (q<0.05).
184
185 **Mendelian Randomization**
186 To further interrogate potential drug targets, we applied MR analyses using the R
187 package TwoSampleMR [38]. For each trait, we performed analyses using local (cis)
188 expression or protein quantitative trait loci (i.e., eQTL or pQTL), generally referred to
189 as xQTLs. We assessed both forward causal relationships (i.e., from molecular trait
190 to GWAS trait) and reverse causal relationships (i.e., from GWAS trait to molecular
191 trait). The Supplementary Material provides details on the handling of potentially
192 pleiotropic and proxy SNPs. Commonly, a single cis-xQTL remained after clumping
193 therefore, the Wald ratio MR method was used. When multiple cis-xQTLs remained
194 after clumping the inverse variance weighted approach was used.
195
196 From brain tissue, we used eQTL data for 18,397 genes from the MetaBrain sample
197 (n=6,518)[39] and pQTL data for 7,553 proteins from the Religious Orders Study
198 (ROS)/Rush Memory and Aging Project (MAP) sample (n=376)[40]. From blood
199 tissue, we used eQTL data for 19,250 genes from eQTLGen sample (n=31,684)[41]
200 and pQTL data for 2938 proteins from the UKB sample (n=34,090)[42]. To avoid
201 sample overlap between eQTLGen with DBP and T2D, we used GTEx v8 eQTL
202 data. In addition, to avoid sample overlap between T2D and UKB, we used the ARIC
203 sample. We performed correction for multiple comparisons across all MR analyses
204 using the Benjamini-Hochberg method (q<0.05).
205

206 **Colocalization**

207 Colocalization analyses help determine if two phenotypes share causal SNPs. For all
208 nominally significant ($p<0.05$) molecular trait associations, we conducted
209 colocalization analyses with the associated GWAS trait using the R package COLOC
210 [43]. We considered the molecular and GWAS trait colocalized when the posterior
211 probability of colocalization was greater than 0.8 (Supplementary Material).
212

213 **Prioritization of Candidate Targets**

214 To generate a ranked list of candidate drug targets for each GWAS trait, we
215 combined evidence across the molecular trait analyses (i.e., XWAS, MR, and
216 colocalization). For each molecular trait analysis (e.g., brain TWAS or blood pQTL
217 colocalization) we normalized association statistics (e.g., Z-scores or PP.H4).
218 Normalized values were generated by dividing the absolute value of the association
219 statistic by the sum of the absolute values across all molecular traits. The resulting
220 normalized values fall between 0 and 1 with larger values representing stronger
221 associations between molecular and GWAS traits. Next, for each molecular trait, the
222 mean normalized value across all analyses, excluding missing values, was used as
223 an overall score. Therefore, molecular traits with the strongest average GWAS
224 associations rank highly without penalization for a lack of representation. A brain-
225 score was generated using the mean normalized values from all brain-tissue
226 analyses. Then, a brain-weighted score was generated as the product of the overall
227 and brain scores. The brain-weighted score provides tissue specificity while also
228 leveraging the large statistical power of blood tissue analyses. This final brain-
229 weighted score was used to rank molecular traits for a given GWAS-trait. For each

230 GWAS trait, we performed a gene-ontology analysis of these candidate targets using
231 the R package clusterProfiler.
232

233 Drug Prioritization

234 Negative Correlation Test

235 We extracted drug-induced gene expression data from Connectivity Map 2020 for all
236 enriched drugs using the phase 2 release of the Library of Integrated Cellular
237 Signatures (LINCS) with the cmapR package (v 4.3.1) [44,45]. For each drug and
238 GWAS trait pairing, a Spearman correlation between drug induced gene expression
239 and variation in molecular trait associations was conducted. Negative correlations
240 indicate the drug may reverse changes in molecular trait abundance associated with
241 the GWAS trait. This “negative correlation test” was run separately for each XWAS
242 and MR analyses and corrections for multiple comparisons were conducted using
243 the Benjamini Hochberg method ($q<0.05$).
244

245 Prioritization of Drugs

246 To prioritize drugs for each GWAS trait, we calculated the mean brain-weighted
247 score across drug-target genes. Therefore, drugs with the strongest molecular trait
248 support were ranked highest. Then a final drug score was generated as the product
249 of the mean brain-weighted score and the normalized fold-enrichment values from
250 GSA-MiXeR. This final score was used to rank drugs for a given GWAS trait. If a
251 negative correlation test was observed for a given drug and GWAS-trait pairing, that
252 drug was moved one place up the ranking given the added supporting evidence.
253

254 **Comparison of Drugs with Variable Efficacy**

255 We assessed genetic support for a list of common antidepressants, antipsychotics,
256 mood stabilizers/anticonvulsants, and stimulants (Supplementary Material). In
257 addition, we assess genetic support for a selection of drugs with failed clinical trials
258 for medications designed to treat psychiatric disorders (Supplementary Material).
259 Here, we assessed the molecular trait support for each drug irrespective of whether
260 the drug was enriched using GSA-MiXeR.

261

262 ## Ethics

263 This study was approved by the Regional Committee for Medical Research Ethics
264 including the use of individual and genetics data from the UKB (accession number
265 27412).

266

267

268 # Results

269 ## Drug Enrichment Analyses

270 We used 9,460 drug gene-sets (Supplementary Table 1) to perform enrichment
271 analyses. GWAS of ADHD, BIP, DEP, and SCZ were enriched for a total of 12, 107,
272 113, and 202 drugs using both GSA-MiXeR (n=34, 152, 283, and 295, respectively;
273 Supplementary Table 2) and MAGMA (n=400, 686, 566, and 713, respectively;
274 Supplementary Tables 3). We observed substantial overlap among the candidate
275 drugs for BIP and SCZ (n=63, p= 3.51e-11) but less among the other psychiatric
276 disorders (BIP-DEP: n=5, p=1.00, DEP-SCZ: n=13, p=1.00) and ADHD only had one
277 overlapping drug with DEP (Figure 1). The ATC code for nervous system drugs

278 (Supplementary Table 4) was enriched, for BIP (n=12/35, p=1.49e-8) and SCZ
279 (n=41/92, p=1.27e-21) but not ADHD (n=1/6, p=0.07) or DEP (n=7/72, p=9.65e-1).
280 Among the top 10 candidate drugs for BIP, DEP, and SCZ were several drugs with
281 antipsychotic properties (e.g., adoprazine, benperidol, cariprazine, mazapertine,
282 nemonapride, piperacetazine, sarizotan, and stepholidine). For ADHD, the top 10
283 candidate drugs were all either pro- or anti-cholinergic drugs.
284
285 As for the comparators, DBP was enriched for 257 drugs and T2D for 95 (n_{GSA-}
286 $_{MiXeR}$=517 and 273, respectively; n_{MAGMA}=1029 and 479, respectively; Supplementary
287 Tables 2 and 3). No significant overlap between candidate drugs for DBP or T2D and
288 the psychiatric disorders was observed (Supplementary Material Figure 1). There
289 was no ATC code enrichment for nervous system drugs (DPB: n=2/163, p=1.00;
290 T2D: n=2/43, p= 9.47e-1) but DBP had enrichment for cardiovascular system drugs
291 (n=80/163, p=5.86e-35) and T2D for alimentary tract and metabolism drugs
292 (n=21/43, p=2.42e-22).



Figure 1. Overlap of Enriched Drugs for Psychiatric Disorders. A network plot depicting each of the enriched drugs (colored nodes) for each psychiatric disorder labelled central hubs. Each drug node is colored based on their level 1 anatomical therapeutic chemical classification. Those nodes without a color (white) represent drugs not assigned an anatomical therapeutic chemical code. The thicker the edge (line connecting nodes to disorder), the larger the fold enrichment. ADHD = Attention deficit hyperactivity disorder, BIP = Bipolar disorder, DEP = Depression, SCZ = Schizophrenia, MULTIPLE = A drug with multiple classifications.

Molecular Trait Analyses

XWAS analyses identified 504, 1142, 1160, and 1855 significant molecular trait associations for ADHD, BIP, DEP, SCZ, respectively (Figure 2, Supplementary Table 5). The molecular traits associated with enriched drugs are labelled in Figure 2 where several were supported by multiple XWAS analyses such as *ANKK1* with DEP. Colocalization analyses revealed 935 (20.06%) of the significant XWAS associations with psychiatric disorders had colocalized genetic signal (Supplementary Tables 6) with enriched drug-target genes depicted in Figure 2 with an asterisk. No significant negative correlation test was observed after correction for multiple comparisons (Supplementary Table 7).



Figure 2. Transcriptome- and Proteome-Wide Association Study Results. For each psychiatric disorder the results of transcriptome- and proteome-wide association studies are presented. Significantly associated molecular traits that are also a part of gene sets for enriched drugs are labelled. Labelled molecular traits that were also colocalized are represented with an asterisk. ADHD: attention deficit hyperactivity disorder, BIP: bipolar disorder, DEP: Depression, SCZ: schizophrenia, TWAS = Transcriptome wide association study, PWAS = Proteome wide association study.

Across the bidirectional MR analyses, 588, 1344, 1462, and 2421 molecular traits were significantly associated with ADHD, BIP, DEP, and SCZ, respectively (Figure 3, Supplementary Table 8). The molecular traits associated with enriched drugs are labelled in Figure 3 where several were supported by multiple MR analyses such as *ADD3* with BIP and *AKT3* with SCZ. Colocalization analyses revealed 694 (11.93%) of the significant MR associations had colocalized genetic signal (Supplementary Tables 9) and with enriched drug-target genes depicted in Figure 3. There were no significant negative correlation tests (Supplementary Tables 10).

329 DBP had 3707 significant XWAS associations and 3112 MR while T2D 1500
330 significant XWAS and 1799 MR associations (Supplementary Tables 5 and 8) with
331 many enriched drug-target genes implicated (Supplementary Material Figures 2 and
332 3). Colocalization was revealed for 614 (16.56%) and 330 (22.00%) XWAS as well
333 as 253 (8.13%) and 186 (10.34%) MR associations for DBP and T2D, respectively
334 (Supplementary Tables 6 and 9). No significant negative correlation test was
335 observed (Supplementary Tables 7 and 10).



Figure 3. Mendelian Randomization Results. For each psychiatric disorder the results of the Mendelian Randomization (MR) analyses are presented. Panel A shows the MR results in the forward direction with the psychiatric disorders as the outcome traits. Panel B shows the MR results in the reverse direction with the psychiatric disorders as the exposure traits. Significantly associated molecular traits that are also a part of a drug gene set enriched for the disorder are labelled. Labelled molecular traits that were also colocalized are represented with an asterisk. ADHD: attention deficit hyperactivity disorder, BIP: bipolar disorder, DEP: Depression, SCZ: schizophrenia, eQTL = expression quantitative trait loci, pQTL = protein quantitative trait loci.

345 **Prioritization of Potential Drug Targets and Compounds**

346 We identified 795, 1657, 1720, and 2650 candidate drug targets supported by at
347 least one molecular trait analysis for ADHD, BIP, DEP, and SCZ, respectively
348 (Supplementary Table 11-14). Among these candidate targets, there was significant
349 overlap observed for BIP with SCZ (n=661, p= 1.79e-19) and DEP (n=359, p=0.02)
350 as well as ADHD and DEP (n=219, p= 2.39e-8). Figure 4 presents the top 10
351 candidate targets for each psychiatric disorder and their supporting evidence. The
352 gene ontology term “glutamatergic synapse" was enriched among the candidate
353 targets for BIP, DEP, and SCZ (Supplementary Table 17). DBP and T2D had many
354 candidate targets (n_{DBP}=4310, n_{T2D}=2191; Supplementary Table 15-16) and some
355 shared gene ontology terms with psychiatric disorders such as “glutamatergic
356 synapse”, “MHC protein complex”, and “early endosome”.
357



Figure 4. Prioritization of Candidate Drug Targets. The list of prioritized potential drug targets for each psychiatric disorder after combining results of molecular trait analyses from transcriptome and proteome wide association studies, Mendelian randomization, and colocalization. ADHD: attention deficit hyperactivity disorder, BIP: bipolar disorder, DEP: Depression, SCZ: schizophrenia, TWAS = Transcriptome wide association study, PWAS = Proteome wide association study, MR = Mendelian randomization, eQTL = expression quantitative trait loci, pQTL = protein quantitative trait loci.

After combining molecular trait support with drug enrichment for each psychiatric disorder, 2 (16.67), 67 (62.62 %), 65 (57.52%), and 116 (57.43%) drugs were supported for ADHD, BIP, DEP, and SCZ, respectively (Supplementary Table 18-21). Figure 5 presents the top 10 prioritized candidate drugs and their supporting evidence. For ADHD, a matrix metalloproteinase inhibitor and acetylcholine receptor agonist were enriched drugs with molecular trait support. For BIP, a mixture of

372 calcium channel blockers, protein kinase inhibitors, and drugs with
373 antipsychotic/antiepileptic properties were top ranked. For DEP, the top 10 drugs
374 included predominantly estrogen related compounds except the top two ranked
375 matrix metalloproteinase inhibitors. For SCZ, seven antipsychotics were among the
376 top 10 ranked drugs.
377
378 DBP and T2D enriched drugs had strong molecular trait support [n_{DBP}=220 (85.60%)
379 and n_{T2D}=64 (67.37%)] (Supplementary Table 22-23). The top 10 candidate drugs for
380 DBP included several approved antihypertensives (e.g., ilepatril, deserpidine, and
381 quinapril). For T2D, the top 10 candidate drugs included several approved for
382 treatment (e.g., repaglinide, mitiglinide, tolbutamide, acetohexamide, and gliclazide).
383
384 Analyses assessing molecular trait support for common psychotropics
385 (Supplementary Table 24) revealed: (i) common stimulants used to treat ADHD,
386 (e.g., methylphenidate) had no molecular trait support, (ii) DEP had molecular trait
387 support for several antidepressants (e.g., duloxetine, clomipramine, and citalopram)
388 but was never the top ranked GWAS trait, (iii) SCZ had molecular trait support and
389 was the top ranked GWAS trait for 10 (e.g., olanzapine, paliperidone, risperidone,
390 and clozapine) antipsychotics followed by BIP then DEP, (iv) BIP had support for
391 several mood stabilizers/anticonvulsants and was the top ranked GWAS trait for
392 lamotrigine (Supplementary Table 24). Among the psychotropics with failed clinical
393 trials (Supplementary Table 25), there was either no molecular trait support for the
394 outcome disorder of the trial (e.g., metadoxine for ADHD, esmethadone for DEP or
395 ulotaront for SCZ), or a low level of support (e.g., brexpiprazole for BIP).



Figure 5. Prioritization of Drug Compounds. The prioritized list of drug compounds (in bold) for each psychiatric disorder with molecular trait support for enriched drugs. In brackets next to each drug compound is the level 1 anatomical therapeutic chemical (ATC) classification code. Below each drug compound is a brief description. In most cases the description is based on the level 3 ATC classification. Drugs without an ATC code use descriptions from various other sources including: PubChem (PC; https://pubchem.ncbi.nlm.nih.gov/), Kyoto encyclopedia of genes and genomes (KEGG; https://www.genome.jp/kegg/kegg2.html), Therapeutic target database (TTD; https://idrblab.net/ttd/). The drug KH-CB19 is a synonym for ethyl 3-[(e)-2-amino-1-cyanoethenyl]-6,7-dichloro-1-methyl-1h-indole-2-carboxylate which is the name used in supplementary materials. nAChR = nicotinic acetylcholine receptor, MMP = Matrix metalloproteinase, DESDP = Diethylstilbestrol Diphosphate, [C] = Cardiovascular system drug, [G] = Genito urinary system and sex hormones, [N] = Nervous system drug, PKC inhib/immunosup. = Protein kinase C inhibitor and immunosuppressant.

409 # Discussion

410 We prioritized potential drug targets and compounds for psychiatric disorders using
411 an extensive genetically informed investigation. Our approach employed novel tools
412 such as GSA-MiXeR [9] for drug gene-set enrichment and the novel use of UKB
413 proteomic data [42] for PWAS of psychiatric disorders. The series of molecular trait
414 analyses revealed candidate drug targets with varying degrees of overlap between
415 the psychiatric disorders. The prioritization of potential drugs revealed known and
416 investigational compounds with indications for psychiatric treatment as well as
417 potential opportunities for repurposing. Altogether, this work highlights the potential
418 utility of genetics for informing psychiatric drug development.
419
420 Top-ranked candidate targets exhibited varying degrees of overlap among the
421 psychiatric disorder and were consistent with previous reports. DCC was among the
422 top ranked candidate targets for DEP and SCZ with previous genetic links to
423 psychiatric disorders [24,46,47]. DCC plays a crucial role in axonal growth during
424 brain development including dopaminergic pathways and developmental disruptions
425 may result in brain structural dysconnectivity linked to various psychiatric disorders
426 [48–50]. Both ADHD and DEP had GPT, an enzyme involved in metabolism of
427 glucose and amino acids such as glutamate, among their top ranked candidate
428 targets which provides a potential link to energy metabolism and glutamate
429 associated neurotransmission. Moreover, sharing of candidate targets between BIP,
430 DEP, and SCZ revealed enrichment for the gene ontology term “excitatory
431 glutamatergic synapse” providing further support for glutamate signalling as a
432 therapeutic target for psychiatric disorders and suggests the need for more

433 therapeutic investigations of glutamate signalling in psychiatry [51,52]. Meanwhile,
434 we and others [12,53] have linked B3GLCT to DEP and since we found only BIP was
435 also associated, B3GLCT may be mood disorder specific. While these findings
436 require further investigation of a wider variety of disorders, revealing potential drug
437 targets specific to a subclass of disorders can be useful for targeting similar cross-
438 disorder symptomology or commonly co-morbid disorders. Many of our top ranked
439 candidate targets have been previously linked to their associated psychiatric
440 disorders in the original GWAS or through various molecular trait analyses.
441 Examples of these associations include: PPP1R16A and LSM6A with ADHD [22];
442 CNNM2, CTNND1, and MKRN1 with DEP [12,23,54]; PDF, PRKCB, and ABCB8
443 with BIP [54]; ASPHD1, DCC, CNNM2, and CYP7B1 with SCZ [24,54]. The
444 consistency across reports further strengthens the support for the prioritized
445 candidate targets.
446
447 Consistent with previous studies, our results provide genetic support for drugs with
448 known or putative indications for psychiatric treatment [6,7,11,31]. In particular, the
449 top 10 prioritized drugs for SCZ included 7 antipsychotics. In addition, we find that
450 drugs with failed clinical trials either have no molecular trait support for their
451 indicated disorder or were ranked low on the list of prioritized drugs. These findings
452 help validate our approach for prioritizing drugs. However, our findings also reveal a
453 lack of genetic support for stimulants for treating ADHD [55]. Notably, ADHD had the
454 lowest drug enrichment and molecular trait associations which likely reflect the lower
455 power of the GWAS compared to the other psychiatric traits. Therefore, with future

456 larger GWAS, a clearer picture of the genetic architecture of psychiatric disorders will
457 be revealed and can be further leveraged to inform drug development.
458
459 Identified drugs in our study additionally highlight opportunities for repurposing. The
460 majority of enriched drugs for ADHD modulate acetylcholine receptors and one
461 agonist (CP-601927) had candidate target support, which is in line with the
462 previously proposed use of cholinergic drugs for ADHD treatment [56]. Top ranked
463 drugs for ADHD and DEP included matrix metalloproteinase (MMP) inhibitors which
464 have been proposed as a new avenue for drug development and repurposing in
465 psychiatrics [57]. MMPs are involved in synaptic remodelling and inflammatory
466 responses in the brain and have been linked to various psychiatric disorders [57].
467 After MMP inhibitors, the top ranked drugs for DEP were predominantly estrogen
468 modulators which have previously been linked to DEP but are not currently indicated
469 treatment [58–60]. While estrogen is a female sex hormone it's modulation as a
470 putative therapeutic target may be relevant for both males and females [61–63].
471 More work is needed to understand the sex-specific genetic support for psychiatric
472 drug development where sex-stratified analyses are critical.
473
474 Combining enrichment with molecular trait analyses revealed important clinical
475 implications for enriched drug targets. Across several analyses and consistent with
476 previous reports, genetic liability to SCZ was associated with reduced expression of
477 *CYP2D6*, an enriched drug target that plays a role in metabolism of
478 neurotransmitters and drugs, including antipsychotics [14,64–66]. Therefore, lower
479 levels of *CYP2D6* may contribute to SCZ pathophysiology and also disrupt treatment

480 response which supports efforts for therapeutic monitoring of *CYP2D6*
481 polymorphisms and evidence-based drug dosing [14,67]. ANKK1 was negatively
482 associated with DEP in several analyses, includes a polymorphism linked to
483 reductions in dopamine receptor abundance, and is a target for several psychotropic
484 drugs [68,69]. Therefore, while many antipsychotics have high affinity for both
485 dopamine and serotonin receptors [70], ANKK1 may be an alternative link for
486 response to antipsychotics in patients with DEP. Consistent with previous reports,
487 BIP and SCZ were associated with candidate targets related to cellular calcium
488 supporting the prioritization of calcium channel blockers for BIP and their continued
489 investigation as therapeutic drugs in psychiatry [7,14,71]. Altogether, these current
490 drug targets revealed important implications for drug development.
491
492 This study has several strengths and limitations. Using DBP and T2D as
493 comparators revealed a lack of overlap in candidate drug targets and enriched drug
494 compounds with any psychiatric disorder and showed the generalizability of our
495 approach beyond psychiatric disorders. A limitation to our MR analyses is the
496 potential for weak instrument bias particularly when using a single instrument
497 approach. This may bias results towards the null leading to a failure to detect true
498 relationships between molecular traits and GWAS traits [38]. Our approach
499 prioritizes drugs irrespective of effect direction. Therefore, we identify drugs with
500 genetic evidence for beneficial or detrimental effects for a trait. While this is useful,
501 our findings require careful interpretation and further investigation. We also use
502 transcriptomic and proteomic data from both brain and blood tissue. The molecular
503 traits and tissue sources are complimentary but not completely correlated.

504 Nevertheless, their integration improves the power to identify modifiable drug targets
505 [72,73]. Our findings may lack generalizability beyond individuals of European
506 ancestry due in part to the reliance of tools on European references and a lack of
507 well powered non-European GWASs and sources of molecular trait data.
508 Additionally, the power of the included GWAS traits vary, which likely contributes to
509 greater drug enrichment and molecular support for GWAS traits with higher power
510 (i.e., SCZ and DBP) compared to those with lower power (i.e., ADHD). This power
511 discrepancy also effects the observed overlap across GWAS traits.
512
513 In conclusion, our extensive analytical approach leveraged psychiatric GWAS
514 combined with novel tools and molecular trait data to prioritize potential drug targets
515 and compounds. The candidate targets can be used for future development of
516 psychotropics. Meanwhile, the prioritized drugs can be used for future repurposing
517 efforts. This study provides clinically relevant evidence for how psychiatric genetics
518 can inform future drug development and repurposing with the potential to improve
519 patient outcomes.
520
521
522 **Data Availability Statement**
523 All GWAS summary statistics and molecular trait data included in this study are
524 publicly available. We generated PWAS weights using proteomic data from the UK
525 Biobank and have shared those weights on figshare
526 [https://doi.org/10.6084/m9.figshare.31487881]. The GWAS summary statistics from

527 the Million Veteran Program were downloaded from the dbGaP web site, under

528 accession phs001672.

References

1. Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic evidence on clinical success. Nature. 2024:1–6.
2. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47:856–860.
3. Linden M, Schermuly-Haupt M-L. Definition, assessment and rate of psychotherapy side effects. World Psychiatry. 2014;13:306–309.
4. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119–136.
5. Solovieff N, Cotsapas C, Lee PH, Purcell SM, Smoller JW. Pleiotropy in complex traits: challenges and strategies. Nat Rev Genet. 2013;14:483–495.
6. Bell N, Uffelmann E, Walree E van, Leeuw C de, Posthuma D. Using genome-wide association results to identify drug repurposing candidates. 2022:2022.09.06.22279660.
7. Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet. 2021;53:817–829.
8. O'Connell KS, Koromina M, Veen T van der, Boltz T, David FS, Yang JM, et al. Genomics yields biological and phenotypic insights into bipolar disorder. 2024:2023.10.07.23296687.
9. Frei O, Hindley G, Shadrin AA, van der Meer D, Akdeniz BC, Hagen E, et al. Improved functional mapping of complex trait heritability with GSA-MiXeR implicates biologically specific gene sets. Nat Genet. 2024;56:1310–1318.
10. Reay WR, Cairns MJ. Advancing the use of genome-wide association studies for drug repurposing. Nat Rev Genet. 2021;22:658–671.
11. Grotzinger AD, Fuente J de la, Davies G, Nivard MG, Tucker-Drob EM. Transcriptome-wide and Stratified Genomic Structural Equation Modeling Identify Neurobiological Pathways Underlying General and Specific Cognitive Functions. 2021.
12. Wingo TS, Liu Y, Gerasimov ES, Gockley J, Logsdon BA, Duong DM, et al. Brain proteome-wide association study implicates novel proteins in depression pathogenesis. Nat Neurosci. 2021;24:810–817.
13. Li X, Shen A, Zhao Y, Xia J. Mendelian Randomization Using the Druggable Genome Reveals Genetically Supported Drug Targets for Psychiatric Disorders. Schizophrenia Bulletin. 2023;49:1305–1315.
14. Liu J, Cheng Y, Li M, Zhang Z, Li T, Luo X-J. Genome-wide Mendelian randomization identifies actionable novel drug targets for psychiatric disorders. Neuropsychopharmacol. 2023;48:270–280.
15. Deng Y-T, Ou Y-N, Wu B-S, Yang Y-X, Jiang Y, Huang Y-Y, et al. Identifying causal genes for depression via integration of the proteome and transcriptome from brain and blood. Mol Psychiatry. 2022;27:2849–2857.
16. Lu T, Forgetta V, Greenwood CMT, Zhou S, Richards JB. Circulating Proteins Influencing Psychiatric Disease: A Mendelian Randomization Study. Biological Psychiatry. 2023;93:82–91.
17. Namba S, Konuma T, Wu K-H, Zhou W, Okada Y. A practical guideline of genomics-driven drug discovery in the era of global biobank meta-analysis. Cell Genomics. 2022;2:100190.
18. Sadler MC, Auwerx C, Deelen P, Kutalik Z. Multi-layered genetic approaches to identify approved drug targets. Cell Genomics. 2023;3:100341.

19. Reay WR, Geaghan MP, Atkins JR, Carr VJ, Green MJ, Cairns MJ. Genetics-informed precision treatment formulation in schizophrenia and bipolar disorder. The American Journal of Human Genetics. 2022;109:1620–1637.
20. Koscielny G, An P, Carvalho-Silva D, Cham JA, Fumis L, Gasparyan R, et al. Open Targets: a platform for therapeutic target identification and validation. Nucleic Acids Research. 2017;45:D985–D994.
21. Koch E, Kauppi K, Chen C-H. Candidates for drug repurposing to address the cognitive symptoms in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2023;120:110637.
22. Demontis D, Walters GB, Athanasiadis G, Walters R, Therrien K, Nielsen TT, et al. Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nat Genet. 2023;55:198–208.
23. Als TD, Kurki MI, Grove J, Voloudakis G, Therrien K, Tasanko E, et al. Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric disorders using genome-wide analyses. Nat Med. 2023;29:1832–1844.
24. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature. 2022;604:502–508.
25. Evangelou E, Warren HR, Mosen-Ansorena D, Mifsud B, Pazoki R, Gao H, et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2018;50:1412–1425.
26. Mahajan A, Spracklen CN, Zhang W, Ng MCY, Petty LE, Kitajima H, et al. Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation. Nat Genet. 2022;54:560–572.
27. Giri A, Hellwege JN, Keaton JM, Park J, Qiu C, Warren HR, et al. Trans-ethnic association study of blood pressure determinants in over 750,000 individuals. Nat Genet. 2019;51:51–62.
28. Vujkovic M, Keaton JM, Lynch JA, Miller DR, Zhou J, Tcheandjieu C, et al. Discovery of 318 new risk loci for type 2 diabetes and related vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. Nat Genet. 2020;52:680–691.
29. Cannon M, Stevenson J, Stahl K, Basu R, Coffman A, Kiwala S, et al. DGIdb 5.0: rebuilding the drug–gene interaction database for precision medicine and drug discovery platforms. Nucleic Acids Research. 2024;52:D1227–D1235.
30. Cheng W, Parker N, Karadag N, Koch E, Hindley G, Icick R, et al. The relationship between cannabis use, schizophrenia, and bipolar disorder: a genetically informed study. The Lancet Psychiatry. 2023;10:441–451.
31. Bipolar Disorder Working Group of the Psychiatric Genomics Consortium 23andMe Research Team, O'Connell KS, Koromina M, Forstner AJ, McQuillin A, Florio AD, et al. Genetic diversity enhances gene discovery for bipolar disorder. 2023:2023.10.07.23296687.
32. De Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. PLoS Comput Biol. 2015;11:1004219–1004219.
33. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BWJH, et al. Integrative approaches for large-scale transcriptome-wide association studies. Nat Genet. 2016;48:245–252.
34. Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science. 2018;362.

35. Ardlie KG, DeLuca DS, Segrè AV, Sullivan TJ, Young TR, Gelfand ET, et al. The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans. Science. 2015;348:648–660.
36. Wingo AP, Liu Y, Gerasimov ES, Vattathil SM, Liu J, Cutler DJ, et al. Sex differences in brain protein expression and disease. Nat Med. 2023;29:2224–2232.
37. Zhang J, Dutta D, Köttgen A, Tin A, Schlosser P, Grams ME, et al. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat Genet. 2022;54:593–602.
38. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife. 2018;7:e34408.
39. de Klein N, Tsai EA, Vochteloo M, Baird D, Huang Y, Chen C-Y, et al. Brain expression quantitative trait locus and network analyses reveal downstream effects and putative drivers for brain-related diseases. Nat Genet. 2023:1–12.
40. Wingo AP, Liu Y, Gerasimov ES, Gockley J, Logsdon BA, Duong DM, et al. Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer's disease pathogenesis. Nat Genet. 2021;53:143–146.
41. Võsa U, Claringbould A, Westra H-J, Bonder MJ, Deelen P, Zeng B, et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat Genet. 2021;53:1300–1310.
42. Sun BB, Chiou J, Traylor M, Benner C, Hsu Y-H, Richardson TG, et al. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023;622:329–338.
43. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al. Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. PLOS Genetics. 2014;10:e1004383.
44. Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 2017;171:1437-1452.e17.
45. Enache OM, Lahr DL, Natoli TE, Litichevskiy L, Wadden D, Flynn C, et al. The GCTx format and cmap{Py, R, M, J} packages: resources for optimized storage and integrated traversal of annotated dense matrices. Bioinformatics. 2019;35:1427–1429.
46. Lee PH, Anttila V, Won H, Feng Y-CA, Rosenthal J, Zhu Z, et al. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell. 2019;179:1469-1482.e11.
47. Smeland OB, Wang Y, Frei O, Li W, Hibar DP, Franke B, et al. Genetic Overlap Between Schizophrenia and Volumes of Hippocampus, Putamen, and Intracranial Volume Indicates Shared Molecular Genetic Mechanisms. Schizophrenia Bulletin. 2018;44:854–864.
48. Vosberg DE, Leyton M, Flores C. The Netrin-1/DCC guidance system: dopamine pathway maturation and psychiatric disorders emerging in adolescence. Mol Psychiatry. 2020;25:297–307.
49. Parker N, Cheng W, Hindley GFL, Parekh P, Shadrin AA, Maximov II, et al. Psychiatric disorders and brain white matter exhibit genetic overlap implicating developmental and neural cell biology. Mol Psychiatry. 2023:1–9.
50. Repple J, Gruber M, Mauritz M, de Lange SC, Winter NR, Opel N, et al. Shared and Specific Patterns of Structural Brain Connectivity Across Affective and Psychotic Disorders. Biological Psychiatry. 2023;93:178–186.
51. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry. 2004;9:984–997.

52. Leucht S, Siafis S, McGrath JJ, McGorry P, Howes OD, Tamminga C, et al. Schizophrenia. Nat Rev Dis Primers. 2025;11:83.
53. Howard DM, Adams MJ, Shirali M, Clarke T-K, Marioni RE, Davies G, et al. Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways. Nat Commun. 2018;9:1470.
54. Wingo AP, Liu Y, Vattathil SM, Gerasimov ES, Mei Z, Ravindran SP, et al. Multiancestry brain pQTL fine-mapping and integration with genome-wide association studies of 21 neurologic and psychiatric conditions. Nat Genet. 2025;57:2156–2165.
55. Quintero J, Gutiérrez-Casares JR, Álamo C. Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review. Neurol Ther. 2022;11:1489–1517.
56. Potter AS, Schaubhut G, Shipman M. Targeting the Nicotinic Cholinergic System to Treat Attention-Deficit/Hyperactivity Disorder: Rationale and Progress to Date. CNS Drugs. 2014;28:1103–1113.
57. Kaczmarek KT, Protokowicz K, Kaczmarek L. Matrix metalloproteinase-9: A magic drug target in neuropsychiatry? Journal of Neurochemistry. 2024;168:1842–1853.
58. Adams MJ, Streit F, Meng X, Awasthi S, Adey BN, Choi KW, et al. Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies. Cell. 2025;188:640-652.e9.
59. de Novaes Soares C, Almeida OP, Joffe H, Cohen LS. Efficacy of Estradiol for the Treatment of Depressive Disorders in Perimenopausal Women: A Double-blind, Randomized, Placebo-Controlled Trial. Archives of General Psychiatry. 2001;58:529–534.
60. Lorsch ZS, Loh Y-HE, Purushothaman I, Walker DM, Parise EM, Salery M, et al. Estrogen receptor α drives pro-resilient transcription in mouse models of depression. Nat Commun. 2018;9:1116.
61. Stanikova D, Luck T, Bae YJ, Thiery J, Ceglarek U, Engel C, et al. Increased estrogen level can be associated with depression in males. Psychoneuroendocrinology. 2018;87:196–203.
62. Carrier N, Saland SK, Duclot F, He H, Mercer R, Kabbaj M. The Anxiolytic and Antidepressant-like Effects of Testosterone and Estrogen in Gonadectomized Male Rats. Biological Psychiatry. 2015;78:259–269.
63. Albert KM, Newhouse PA. Estrogen, Stress, and Depression: Cognitive and Biological Interactions. Annual Review of Clinical Psychology. 2019;15:399–423.
64. Bertilsson L, Dahl M-L, Dalén P, Al-Shurbaji A. Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. British Journal of Clinical Pharmacology. 2002;53:111–122.
65. Ma L, Shcherbina A, Chetty S. Variations and expression features of CYP2D6 contribute to schizophrenia risk. Mol Psychiatry. 2021;26:2605–2615.
66. Wang X, Li J, Dong G, Yue J. The endogenous substrates of brain CYP2D. European Journal of Pharmacology. 2014;724:211–218.
67. Milosavljević F, Bukvić N, Pavlović Z, Miljević Č, Pešić V, Molden E, et al. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure. JAMA Psychiatry. 2021;78:1–11.
68. Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: A novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Human Mutation. 2004;23:540–545.
69. Suzuki A, Mihara K, Kondo T, Tanaka O, Nagashima U, Otani K, et al. The relationship between dopamine D2 receptor polymorphism at the Taq1 A locus and therapeutic

response to nemonapride, a selective dopamine antagonist, in schizophrenic patients. Pharmacogenetics and Genomics. 2000;10:335.

70. Meltzer HY. The Role of Serotonin in Antipsychotic Drug Action. Neuropsychopharmacol. 1999;21:106–115.

71. Cipriani A, Saunders K, Attenburrow M-J, Stefaniak J, Panchal P, Stockton S, et al. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Mol Psychiatry. 2016;21:1324–1332.

72. Manzoni C, Kia DA, Vandrovcova J, Hardy J, Wood NW, Lewis PA, et al. Genome, transcriptome and proteome: the rise of omics data and their integration in biomedical sciences. Briefings in Bioinformatics. 2018;19:286–302.

73. Qi T, Wu Y, Zeng J, Zhang F, Xue A, Jiang L, et al. Identifying gene targets for brain-related traits using transcriptomic and methylomic data from blood. Nat Commun. 2018;9:2282.

Acknowledgments

We thank all participants, staff, and providers of the publicly available data used in this study including individuals from the UKB, psychiatric genomics consortium, Million Veterans Program, PsychENCODE, ARIC, MetaBrain, ROS/MAP, eQTLGen, GTEx.

Author Contributions

NP and OBS conceived of the study and EK, AAS, GFLH, SS, PJ, KSO, and OAA were involved in study design. NP, EK, AAS, TSW, and APW were involved in data acquisition and processing. NP, EK, AAS, and JF were involved in data analysis. NP had access to all data and drafted the initial manuscript. All authors contributed to data interpretation and editing of the manuscript and accepted responsibility to submit the manuscript for publication.

Funding

Funding was provided by the US National Institutes of Health (grants U24DA041123, R01AG076838, U24DA055330, OT2HL161847 and 5R01MH124839-02), the Research Council of Norway (grants 296030, 273291, 273446, 300309, 324252, 326813, 334920), the South-East Regional Health Authority (grant 2022–073), EEA-RO-NO-2018–0573, EEA-RO-NO-2018–0535, EU's Horizon 2020 Research and Innovation Programme (grant 847776; CoMorMent and 964874 REALMENT), Novo Nordisk Foundation (grant NNF23OC0099658), the Marie Skłodowska-Curie Actions Grant 801133 (Scientia fellowship). This work was performed on Services for sensitive data (TSD), University of Oslo, Norway, with resources provided by

UNINETT Sigma2 - the National Infrastructure for High Performance Computing and Data Storage in Norway (NS9666S).

Competing Interest

OAA has received speaker fees from Lundbeck, Janssen, Otsuka, and Sunovion and is a consultant to Cortechs.ai. and Precision Health. AMD is Founding Director, holds equity in CorTechs Labs, Inc. (DBA Cortechs.ai), and serves on its Board of Directors and the Scientific Advisory Board. He is an unpaid consultant for Oslo University Hospital. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. OF is a consultant to Precision Health. TSW is a co-founder of revXon, which is disclosed and approved to University of California, Davis per its conflict-of-interest policy. All other authors report no biomedical financial interests or potential conflicts of interest.